Lecanemab: A Promising Treatment for Alzheimer's Disease

Lecanemab, a monoclonal antibody targeting amyloid beta, has received accelerated FDA approval for the treatment of Alzheimer's Disease (AD) due to its demonstrated efficacy in reducing amyloid beta plaques. It has now transitioned to traditional approval, making it a promising treatment option for AD. Lecanemab has shown a reduction in amyloid beta plaques and has fewer reported adverse effects compared to aducanumab. It is covered by Medicare and Medicaid, but patients may still face financial burden due to out-of-pocket costs. Lecanemab provides hope for patients and caregivers seeking a treatment for AD.